B-cell receptor (BCR) is a B cell hallmark surface complex regulating multiple cellular
processes in normal as well as malignant B cells. Igα (CD79a)/Igβ (CD79b) are essential …

Blood cancers are characterized by pathological disorders causing uncontrolled
hematological cell division. Various strategies were previously explored for the treatment of …

Background The functions of HULC have been demonstrated in several cancers. However,
its mechanism has not been elucidated in human liver cancer stem cells. Methods Liver …

Simple Summary Venetoclax is an antagonist of the antiapoptotic protein Bcl-2, and is
currently approved for treatment of chronic lymphocytic leukemia (CLL). Recently, clinical …

Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the adult
population. From an asymptomatic state, which can lay for years, CLL rapidly evolves …

B-cell receptor (BCR) signaling plays a major role in the pathogenesis of B-cell
malignancies and is an established target for therapy, including in chronic lymphocytic …

Simple Summary Despite continued efforts, the current status of knowledge in CLL
molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise …

Identifying precise targets of individual cancers remains challenging. Chronic lymphocytic
leukemia (CLL) represents the most common adult hematologic malignancy, and trisomy 12 …

Chronic lymphocytic leukemia (CLL) mainly afflicts adults and accounts for 25% of all new
leukemia cases. CLL progresses slower than other types of leukemia do, so many people do …

Venetoclax (VCX) is a BCL2 inhibitor approved for treating B cell-derived leukemia,
including chronic lymphocytic leukemia (CLL). VCX's role in apoptosis induction is well …